An important mechanism of action of metformin as an antidiabetic drug involves inhibition of
hepatic gluconeogenesis, but the molecular basis for this is controversial. A recent …

Introduction Metformin, an oral hypoglycemic agent, was introduced in the clinical practice
for the treatment of type 2 diabetes mellitus more than a half-century ago. Over the years …

Laboratory research and pharmacoepidemiology are providing converging evidence that
the widely used antidiabetic drug metformin has antineoplastic activity, but there are …

The anti-diabetic drug metformin is rapidly emerging as a potential anti-cancer agent.
Metformin, effective in treating type 2 diabetes and the insulin resistance syndromes …

Metformin, an inexpensive, well-tolerated oral agent that is commonly used in the first-line
treatment for type 2 diabetes, has become the focus of intense research as a potential …

Metformin is one of the most widely used anti-diabetic agents in the world, and a growing
body of evidence suggests that it may also be effective as an anti-cancer drug …

Metformin has been the mainstay of therapy for diabetes mellitus for many years; however,
the mechanistic aspects of metformin action remained ill-defined. Recent advances revealed …

Metformin exhibits anticancer properties and is currently being explored as a therapeutic
option for a variety of cancer types. Epidemiological studies demonstrate associations …

Metformin has been used for nearly a century to treat type 2 diabetes mellitus. Epidemiologic
studies first identified the association between metformin and reduced risk of several …

Metformin is the first-line treatment for type 2 diabetes. Results from several clinical studies
have indicated that type 2 diabetic patients treated with metformin might have a lower cancer …